

Diagnosis and Management of Venous Thromboembolism: Deep Vein Thrombosis (DVT) Procedure

Classification

Clinical

Supersedes:

457A

Guideline

Number:

number.							
Version No:		ate of EqIA:	Approved by:		Date Approved:	Date made active:	Review Date:
5	5		Thrombosis (Thrombosis Committee		31/7/2018	26/7/2021
Brief Summary of Document:		It is a standardised diagnostic pathway for patients presenting with suspected deep vein thrombosis. It outlines key principles in relation to the diagnosis and management of DVT in an outpatient setting. It is to be used across the Health Board so that all patients are assessed, diagnosed and treated in accordance with current NICE recommendations.					
Scope		This procedure is to be used for the diagnosis and treatment of deep vein thrombosis in adults in the acute and outpatient setting. It does not include the management of pulmonary embolus. The management of deep vein thrombosis in children and obstetric patients are excluded from this procedure.					
To be read in conjunction with:		482 - Anticoagulation Discharge Referral Information Procedure					
Owning committee		Thromb	oosis Committee				

Glossary of terms

Term	Definition
DVT	Deep Vein Thrombosis
PE	Pulmonary Embolism
COAD	Chronic Obstructive Airways Disease
VTE	Venous Thromboembolism
LMWH	Low Molecular Weight Heparin
FBC	Full Blood Count
LFT	Liver Function Test
INR	International Normalised Ratio
BP	Blood Pressure

Deep Vein Thrombosis, DVT, Venous Thromboembolism, VTE, Thromboprophylaxis, Thrombosis, Anticoagulation, LMWH, Warfarin,
Rivaroxaban, Apixaban, Wells score.

Version number	Approval date	Comments
1	May 2015	New document
2	4.12.2015	Updated following NICE guidance
3	16.9.2016	Correction on page 11
4	1.6.2018	Full review
5	25.7.2018	Minor amendments

CONTENTS

1.		NTR	ODUCTION	4
2.	;	SCO	PE	4
3.	4	AIM.		4
5.	ı	MON	ITORING COMPLIANCE	4
6.	ı	PRO	CEDURE	4
6	.1	OV	ERVIEW OF DEEP VEIN THROMBOSIS	4
	6.	1.1	CLINICAL FEATURES:	4
	6.	1.2	RISK FACTORS:	5
6	.2	CR	ITERIA FOR ASSESSMENT	5
	6.2	2.1	INCLUSION CRITERIA:	5
	6.2	2.2	EXCLUSION CRITERIA:	5
6	.3	DIA	AGNOSIS	5
6	.4		EATMENT	
6	.5	MC	ONITORING OF TREATMENT	6
6	.6	DU	RATION OF ANTICOAGULATION	6
6			/ESTIGATIONS FOR PATIENTS WITH CANCER	
7	I	REFE	ERENCES	8
			1: TWO-LEVEL DVT WELLS SCORE FOR DIAGNOSIS OF DEEP VEIN	
THE	RO	МВО	SIS (DVT)	9
APPENDIX 2: ALGORITHM FOR DIAGNOSIS OF DVT10				
APPENDIX 3: PROFORMA FOR THE ASSESSMENT OF AN OUT-PATIENT WITH				
SUS	SPI	ECTE	ED DVT1	1

1. INTRODUCTION

Deep vein thrombosis (DVT) is a common disorder with an annual incidence of 1 or 2 cases per 1000 persons in the general population. Anticoagulation is an effective treatment but on discontinuation the risk of recurrence remains and can reach 10% during the first year.

2. SCOPE

This procedure is to be used by competent staff for the assessment, diagnosis and treatment of suspected or proven deep vein thrombosis in adults in the outpatient setting. It does not include the management of pulmonary embolus.

The management of deep vein thrombosis in children and obstetric patients are excluded from this procedure.

- All medically qualified doctors are able to follow the procedure as they are competent in history taking, clinical examination and are able to prescribe the required medications.
- Counselling following diagnosis can be carried out by competent nurses who have completed the Birmingham anticoagulant course.

3. **AIM**

The aim of the procedure is to standardise the diagnosis and management of DVT across the Health Board, so that all patients presenting with suspected or proven deep vein thrombosis are assessed, diagnosed and treated appropriately, and therefore do not come to avoidable harm.

4. OBJECTIVES

The aim of the procedure is achieved by:

- The appropriate assessment of patients with suspected DVT
- The timely diagnosis of patients with proven DVT
- The appropriate treatment of patients with proven DVT

5. MONITORING COMPLIANCE

The NICE audit tool (NICE CG144 2012)¹⁴, Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing must be used, with an annual audit undertaken in each acute hospital.

6. PROCEDURE

6.1 Overview of deep vein thrombosis

6.1.1 Clinical Features:

The clinical features of a deep vein thrombosis are variable. Patients may present with the following symptoms in their leg:

- Swelling
- Pain
- Redness
- Warmth

Signs of a DVT on examination include:

- Tenderness
- Warmth
- Erythema
- Cyanosis
- Palpable thrombotic vein
- Superficial venous dilation

6.1.2 Risk Factors:

The cause of a DVT is often multifactorial.

- Surgery
- Malignancy
- Prolonged bed rest
- Immobility/Pregnancy/recent childbirth
- Family history of venous thromboembolism
- Obesity
- Inherited thrombophilic defect
- Antiphospholipid syndrome
- Advanced age
- Chronic obstructive airways disease (COAD)
- Congestive cardiac failure
- Oral contraceptive pill/Hormone replacement therapy
- Intravenous drug users
- Steroid treatment

6.2 Criteria for assessment

6.2.1 <u>Inclusion criteria:</u>

Patients presenting with a clinical suspicion of a DVT

6.2.2 Exclusion Criteria:

- Suspected or confirmed pulmonary embolus
- Thrombus in the iliac veins or vena cava
- Active bleeding e.g. intracranial bleed within last 6 months, gastro-intestinal bleed within 1 month, oesophageal varices
- Verified bleeding disorder e.g. haemophilia or thrombocytopenia(Platelets <90x10/L)
- Pregnancy
- Known liver failure
- Hypertension, systolic BP>180mm Hg or diastolic BP 115mmHg
- Age < 16years
- No fixed address
- Not contactable by phone
- Inability to understand instructions
- Anticipated compliance problems e.g. mental illness or alcohol misuse

6.3 Diagnosis

Refer to Appendices 1, 2 and 3 for the Wells Score table algorithm and assessment proforma for the outpatient assessment of patients with suspected DVTs

Appendix 3 – the DVT Assessment Proforma must be completed accurately and fully, as failure to do so may result in delays in scanning.

Referrals from Primary Care for Doppler investigations, must be accompanied with the completed DVT Assessment Proforma.

6.4 Treatment

6.4.1 Treatment for a first episode DVT:

The choice of treatment for a first episode DVT is:

- 1. Apixaban
- 2. Rivaroxaban

OR

3. Low molecular weight heparin initially followed by Warfarin. (agent of choice for patients below 40kg or above 120kg of weight)

All patients initiated on anticoagulation need the Anticoagulation Discharge Referral Form completed; refer to Hywel Dda UHB Procedure 482 - Anticoagulation Discharge Referral Information

6.4.2 Treatment for recurrent DVT:

The choice of treatment for recurrent DVT is:

1. Low molecular heparin and Warfarin

6.5 Monitoring of treatment

Patients on Warfarin will have INRs performed either in Primary Care if the GP practice is a 'level 3 or 4 Centre' or Secondary Care.

6.6 Duration of anticoagulation

The current all Wales adult in-patient Warfarin chart outlines the current recommended length of treatment for venous thromboemboli as follows:

- 1st idiopathic VTE: proximal DVT or PE >3months or longer (as determined by the consultant in charge of the patient)
- 1st proximal VTE/PE with precipitating factors e.g. trauma, surgery, pregnancy: 3 months
- 1st idiopathic, calf vein DVT: 3 months
- 1st calf vein DVT, with precipitating factors eg trauma, surgery: 6 weeks
- Recurrent VTE: long term
- VTE whilst taking Warfarin (discuss with haematologist): long term

6.7 Investigations for Patients with Cancer.

All patients with an unprovoked DVT must have a full history and examination to guide further investigations. Other investigations to perform are:

- A chest X-ray and
- Blood tests (FBC, serum calcium and LFT) and
- Urinalysis

Consider further investigations for cancer with an abdomino-pelvic CT scan (and a mammogram for women) in all patients aged over 40 years with a first unprovoked DVT who do not have signs or symptoms of cancer based on initial investigation

Cancer needs to be considered as a possible cause of a DVT particularly in the elderly, patients with bilateral DVTs, recurrent DVTs, markedly raised D-dimers at presentation or raised inflammatory markers.

Patients with cancer-associated VTE are at high risk of recurrence and LMWH has been shown to be more effective than warfarin for the first 6 months of treatment (Lee et al, 2003). The British Journal of Haematology recommends that **patients with cancer-associated VTE**

should initially be treated for 6 months with therapeutic dose LMWH rather than warfarin.

7 REFERENCES

- NICE CG144 Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of Thrombophilia testing. December 2015. Accessed via: http://www.nice.org.uk/
- NICE TA261 Rivaroxaban[▼] for the treatment of deep vein thrombosis, and prevention of recurrent DVT and pulmonary embolism. July 2012. Accessed via: http://www.nice.org.uk/
- Summary of product characteristics for rivaroxaban (Xarelto Bayer DOR 05/2012).
 Accessed: http://www.medicines.org.uk/EMC/medicine/ See also: BNF 64 September 2012.Rivaroxaban . Drugdex. Accessed (via e-library HOWIS)
 http://www.thomsonhc.com/micromedex2/librarian/ 26 November 2012
- National Centre for Anticoagulation Training (NCAT), University of Birmingham.
 Available

 http://www.birmingham.ac.uk/research/activity/mds/projects/HaPS/PCCS/anticoagulation/index.aspx [accessed 20th August 2015]
- Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine. 2003; 349(2):146-153.
- NICE Clinical Guidance CG144: Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. Published June 2012. Available at: http://www.nice.org.uk/guidance/CG144 [accessed 20th August 2015]
- NICE Evidence Update CG144 Venous thromboembolic diseases. Published June 2014.Available at: http://www.nice.org.uk/guidance/cg144/evidence/cg144-venous-thromboembolic-diseases-evidence-update2 [accessed 20th August 2015]


APPENDIX 1: TWO-LEVEL DVT WELLS SCORE FOR DIAGNOSIS OF DEEP VEIN THROMBOSIS (DVT)

Adapted by NICE (CG144) with permission from Wells PS et al (2003).

Clinical feature	Points		
Active cancer (treatment ongoing, within 6 months, or palliative)	1		
Paralysis, paresis or recent plaster immobilisation of the lower extremities	1		
Recently bedridden for 3 days or more or major surgery within 12 weeks requiring general or regional anaesthesia	1		
Localised tenderness along the distribution of the deep venous system	1		
Leg swollen	1		
Calf swelling at least 3cm larger than asymptomatic side	1		
Pitting oedema confined to the symptomatic leg	1		
Collateral superficial veins (non-varicose)	1		
Previously documented DVT	1		
An alternative diagnosis is at least as likely as DVT	-2		
Clinical probability simplified score			
DVT likely	2 points or more		
DVT unlikely	1 point or less		

APPENDIX 2: ALGORITHM FOR DIAGNOSIS OF DVT

(Adapted from NICE CG144)



Database No: 457A Page 10 of 13 Version 5.0

APPENDIX 3: PROFORMA FOR THE ASSESSMENT OF AN OUT-PATIENT WITH SUSPECTED DVT

DVT Investigation Proforma		Hywel Dda Health Board			
		Hospital:			
		Name of Clinician:			
1. Patient Identifier:	Referred by (please tick):				
Name					
		GP □ A&E □ AMAU □ Other □			
		GP details			
Hospital number					
DOB					
Address					
Address		Next of Kin			
		Next of Kill			
Telephone number		Next of Kin Contact Number			
2. Pre-test probability (PTP)		O. Annalis and Market Company			
Two level DVT Wells score		3. Are they suitable for OPD treatment?			
Active cancer in the last 6/12	1	No, for the reasons below:			
Paralysis, paresis or recent leg plaster	1	Suspected or confirmed pulmonary embolus			
Bedridden for >3 days or major surgery in last 4/52	1	Thrombus in the iliac veins or vena cava			
Tenderness along deep venous system	1	Active bleeding (e.g. intracranial bleed within last 6 months, GI bleed within 1 month, oesophageal varices)			
Entire swollen leg	1	Verified bleeding disorder (e.g. Haemophilia or thrombocytopenia – platelets <90x10/L)			
Calf circumference difference >3cm (measured 10cm below tibial tuberosity)	1	Pregnancy			
Pitting Oedema (greater in symptomatic leg)	1	Heparin hypersensitivity or a history of HIT			
Collateral superficial veins (non-varicose)	1	Creatinine clearance <15ml/min			
Previously documented DVT	1	Known liver failure			
Alternative diagnosis seems more likely	-	Hypertension, Systolic BP>180mm Hg or			
than DVT (minus)	diastolic BP >115mm Hg				
Probability score		Age <16 years			
DVT likely: 2 points or more		No fixed address			
DVT unlikely: 1 point or less		Not contactable by phone			

	Inability to understand instr	uctions	
	Anticipated compliance problems e.g.		
	mental illness or alcohol mi	suse.	
	Yes, as none of the above		
4. D-Dimer Result:			
Negative □ Positive □	l		
5. Action (see table 1B)			
 possible). If scan positive treat DVT. If so other diagnosis. If DVT 'likely'- Request proximal leg ultraso imaging and treat DVT if confirmed. If ne performed, perform a D-dimer test and if negative consider other diagnosis. If no proximal leg vein ultrasound scan is a perform D-dimer and offer interim anticoa 	prior to ultrasound scan (within 24 hours if scan negative- unlikely to have DVT consider sound within 4 hours. If available proceed with egative and only a proximal leg scan was f positive repeat scan in 7 days. If D-dimer available within 4 hours of being requested		
negative and D dimer was positive consider		ays	
6. Medical notes	7. Risk factors		
History	 Malignancy 		
	 Surgery in last 6 weeks 		
	 Prolonged bed rest 		
	Long haul flight		
	 Pregnancy/recent childbi 	rth	
	 Family history of venous thromboembolism 		
Past medical history	Obesity		
	 Inherited thrombophilic d 	efect	
	 Antiphospholipid syndror 	ne	
	• Smoker [
	HRT/OCP		
	8. Examination (please tid	ck)	
Medication:	Affected leg	yes	
		no	
	Pain	yes	
		no	
	Swelling	yes	
		no	
	Temperature	yes	
		no	
	Colour change in leg/foot/toe	•	
		no	

Allergies:	Calf circumference: Right
	Left:
	Temp: Pulse:
	BP: Weight:
9. Blood results	10. Ultrasound Results
Fbc U&E	Date of first scan://
Hb Na	Date of second scan://
Wbc K	
Plt Urea	Reason for repeat scan:
Creat	
LFT Coag screen	Result of USS scan:
Bili PT	
Alb APPT	
ALT Fibrinogen	First:
Cockcroft-Gault creatinine clearance:	
(140-age) x weight (kg) x factor*	
Creatinine (um/l)	
* female=1.04, male=1.23	
All results to be copied to GP	Second (if applicable):
Action taken	Additional notes
Information sheet given to patient	
If post-op inform surgeon	
Discharge to GP and letter sent	
Discuss with GP	
Refer to A&E	
Copy filed in patient's notes	